Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Pilot Study of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma

Trial Profile

A Multicenter Pilot Study of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 14 Sep 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jun 2018 According to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology, up to 28 patients will enroll at 4 sites over a 2 year period. Cohorts 1 and 2 have completed enrollment as of February 2018.
    • 05 Jun 2018 Planned number of patients changed from 14 to 28, according to trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top